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Abstract: Primary Sjögren’s syndrome (pSS) patients identify fatigue as their most impor-
tant symptom and the one most difﬁcult to cope with, but there are still many challenges and
few solutions to manage this debilitating symptom. Promising pharmacological treatments,
such as rituximab, have failed in more stringent tests including randomized controlled trials
(RCTs) and meta-analysis. While non-pharmacological interventions may be safer, less
costly, and address other common comorbidities, to date only aerobic exercise seems to be
effective at reducing fatigue in pSS. All interventions, pharmacological or not, need to be
tested in high-quality RCTs. The aim of this review is to provide an overview of fatigue
management in pSS and discuss potential opportunities for future research.
Keywords: primary Sjögren’s syndrome, fatigue, treatment, review
Introduction
Fatigue is a hallmark of many rheumatologic conditions, including primary Sjögren’s
syndrome (pSS). A systemic autoimmune disease characterized by lymphocytic inﬁl-
tration and progressive destruction of exocrine glands, 20–40% of pSS patients present
with severe systemic manifestations.1 Fatigue is reported in up to 70% of the pSS
patients and most patients are also affected by dryness and pain.2
Fatigue is deﬁned by Staud as “a subjective, unpleasant symptom that incorpo-
rates total body feelings ranging from tiredness to exhaustion, creating an unrelent-
ing overall condition that interferes with individuals’ ability to function in their
normal capacity”.3 PSS patients often complain that it is their greatest problem and
the most difﬁcult to cope with.4 They experience a heavy, resistant body and
uncontrollable ﬂuctuating fatigue.5 Fatigue in pSS is chronic, persistent, and
intractable.6,7 In pSS its pathophysiology is unknown, and is likely to involve
multiple factors.
Genetic factors have been postulated for the development of fatigue in pSS,8,9
but there is a paucity of studies to conﬁrm this link. Fatigue in pSS may be linked to
inﬂammatory mechanisms. Hartkamp et al did not ﬁnd any association between the
levels of fatigue and the serum levels of the inﬂammatory markers interleukin
(IL)-1b, IL-2, IL-6, IL-10 and tumor necrosis factor alfa (TNF-α).10 However,
Howard et al showed that lower levels of the pro-inﬂammatory cytokines inducible
protein (IP)-10 and interferon-gamma (IFN-γ), together with pain and depression,
were the most important predictors of fatigue.11 Nonetheless, the evidence for an
association between fatigue and disease activity – or any other inﬂammatory
markers – remains controversial.11–15
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Fatigue is known to be associated with lower aerobic
capacity16 and lower physical activity levels.17,18 Wouters
et al have shown that pSS patients with lower physical
activity, higher activity avoidance, and greater somatic focus
have more severe symptoms of fatigue.19 Fatigue in pSS is
associated with greater functional impairment.20 It is possible
that interventions to increase aerobic capacity and levels of
physical activity may improve the symptoms of fatigue.
PSS patients also present a range of other manifestations
associated with fatigue. These include sleep disturbances,21–23
autonomic dysfunction,24,25 depression,11,13,15,26,27 dysfunc-
tional or alexithymic psychological proﬁle,28 neuroticism,
and ﬁbromyalgia.15 These complex associations and comor-
bidities require appropriate management in clinical practice
based on a multi-disciplinary approach including rheumatolo-
gists and other health professionals.
A growing number of methods have been used to mea-
sure fatigue in pSS studies. Few of them used the speciﬁc
instrument of the pSS, the Proﬁle of Fatigue and Discomfort
(PROFAD), whose fatigue component (Proﬁle of Fatigue-
ProF) measures the somatic (ProF-S) and mental (ProF-M)
fatigue.29,30 Instead, most studies have used a single-item
instrument, the 10-cm VAS, or non-disease speciﬁc multi-
item questionnaires.
Despite VAS popularity, it does not capture the multi-
dimensional nature of fatigue; neither it is able to identify
patients with major fatigue. However, another recent and
speciﬁc disease instrument, the EULAR Sjögren’s
Syndrome Patients Reported Index (ESSPRI), also uses 0
to 10 numerical scales for the assessment of each of the three
domains: dryness, fatigue and musculoskeletal pain.4,31
There are a range of multi-item questionnaires such as
Multidimensional Fatigue Inventory (MFI),32 Fatigue
Severity Scale (FSS),33 Functional Assessment of Cancer
Therapy Scale-fatigue (FACIT-fatigue),34,35 Fatigue Impact
Scale (FIS)36 and Chalder Fatigue Scale (CFS).37
Nevertheless, these instruments were designed initially to
measure fatigue in other disorders and therefore may not
necessarily be suitable for use in pSS.
Fatigue is inversely correlated with health-related qual-
ity of life27,38,39 and with both the physical,40,41 and the
mental components of the SF-36.41 While treatment of this
disabling symptom is likely to improve patients’ daily life,
there is little evidence-based treatment of fatigue. This
makes patient management a real challenge for rheumatol-
ogists and other health professionals. The aim of this review
is to provide an overview on the management of fatigue in
pSS and discuss potential targets for future research.
The main characteristics and outcomes of the selected
studies are summarised in Table 1.
Pharmacological treatment to treat
fatigue in pSS: a real challenge
There is currently no evidence to support pharmacological
treatment of fatigue in pSS. Both biological and non-
biological treatments have been tried in pSS. Despite promis-
ing data from Phase II studies,42–44 two Phase III trials failed to
demonstrate the efﬁcacy of rituximab (RTX) in improving
fatigue in pSS.45,46 It should be noted that for most of these
clinical trials, fatigue is not the primary outcome. Instead, it is
often part of a composite outcome. This may reﬂect the sub-
stantial costs, potential adverse events, and the diversity of
instruments and lack of standard, objective and validated
measurements of fatigue in pSS. For other biological thera-
pies, results from Phase III trials are awaited. In addition, it is
possible that biologic drugs potentially valuable to the treat-
ment of pSS currently under investigation47 may be effective
for fatigue.
Non-biological therapies
Hydroxychloroquine (HCQ) is an antimalarial drug with an
immunomodulatory effect widely prescribed in patients with
pSS reporting extraglandular manifestations, such as fatigue,
arthralgia, arthritis or myalgia. However, evidence support-
ing its efﬁcacy in treating such symptoms are weak, and its
use is based largely on clinical experience and expert
recommendations.48–51 A 2-year double-blind crossover
trial with only 19 patients52 and a 2-year double-blind rando-
mized controlled trial (RCT) with 120 patients53 did not
demonstrate the efﬁcacy of HCQ for fatigue measured by
its severity and VAS, respectively. These studies and one
retrospective study including 50 patients who were taking
HCQ (6–7 mg/kg/day) for at least 2 years54 were included in
a recent meta-analysis. This concluded that the effectiveness
of HCQ was lower than placebo for fatigue and the most
common adverse effects were gastrointestinal side effects.55
Conversely, another multicenter retrospective study includ-
ing 221 patients with at least 1 year of follow-up, showed that
fatigue was less frequent in those on HCQ therapy than those
in the non-treated group (16.7% vs 83.3%, p<0.001).56 Thus
whether HCQ is effective for fatigue in pSS remains unclear
and further research is needed.
Small open-label studies have shown improvement in
general fatigue measured by MFI using leﬂunomide (LEF)
20 mg daily in 15 patients after 24 weeks,57 and in fatigue
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VAS using zidovudine 250mg twice daily in a study including
only seven patients.58 In contrast, dehydroepiandroster
one,59,60 gamma-linolenic acid, an essential omega-6 fatty
acid,61 and doxycycline62 have shown no efﬁcacy in reducing
fatigue in pSS RCTs. More recently, data from a Phase II
clinical trials of a combination therapy using both HCQ and
LEF with 42 patients (28 active arms, 14 placebos) showed
improvement in ESSPRI fatigue.63
There is an interesting case report of a 44-year-old pSS
patient refractory to conventional treatment (prednisone,
azathioprine, and RTX), presenting with severe clinical man-
ifestations including uncontrollable fatigue, headache, and
hyperglobulinemic purpura, treated with bortezomib,
a proteasome inhibitor licensed for the treatment of multiple
myeloma. She showed a notable improvement of the general
symptoms, particularly fatigue VAS, a decrease in serum
globulin levels as well as in serum viscosity, and the return
of the patient to her usual activities.More studies are needed to
determine the safety and efﬁcacy of this drug in patients with
pSS.64
A recent Chinese multicenter RCT demonstrated the
efﬁcacy and safety of total glucosides of peony (TGP) in
320 patients with pSS who did not exhibit signiﬁcant
extra-glandular manifestations. TGP are extracted from
the root of the Paeonia lactiﬂora pall and have been
demonstrated to have immunomodulatory effects, such as
inhibition of dendritic cell maturation and function. The
results showed that ESSPRI scores improved dramatically,
signiﬁcantly alleviated some dryness symptoms, and
improved fatigue VAS during the 24-week trial. The rate
of adverse events in the TGP group was 10.9%; the main
adverse event was diarrhea at a rate of 4.8%.65
Biological therapies
The increasing evidence that B cells play a leading role in
the pSS pathogenesis indicates that RTX, a chimeric anti-
CD20 monoclonal antibody which acts through depletion
of B cells, may be an exciting therapy. A small prospective
open-label study with 16 patients receiving two low-dose
RTX infusions (375 mg/m2)42 and a RCT with 30 patients
(2 infusions of 1000 mg)43 demonstrated an improvement
in fatigue (VAS and MFI, respectively). However, a meta-
analysis has shown that RTX is not able to reduce fatigue
in pSS patients after 24 weeks.66
Improvement in fatigue is also observed in two other
randomized controlled studies with two infusions
(1000 mg) of RTX. In the study by Devauchelle-Pensec
et al with 120 patients, reductions in fatigue VAS were
observed at weeks 6 and 16.45 In the study by Dass et al
with 17 patients, fatigue VAS and PROFAD improvement
was signiﬁcantly higher than the placebo group.44
However, Bowman et al in another larger RCT with
133 patients treated with two courses of RTX therapy
(6 months apart), did not ﬁnd signiﬁcant differences in
fatigue scores (VAS, ESSPRI, and PROFAD) between the
RTX and the placebo arms (MD 5.0, 95% CI −3.37 to
13.37).46 Similarly, a more recent meta-analysis did not
ﬁnd signiﬁcant differences between the RTX and placebo
groups between baseline and week 24 in fatigue VAS
(MD −3.24 95% CI −30.21 to 23.72).67
Belimumab, a monoclonal anti-BAFF antibody, is
a promising biological drug to treat pSS, since 60% of
the patients achieved the primary endpoint, including
fatigue VAS and systemic activity, at week 28 in
a prospective 1-year open-label study including 30 SS
patients with systemic complications. Ten mg/kg of
belimumab was administered at weeks 0, 2, and 4 and
then every 4 weeks up to week 24.68,69
Another small, open-label study including 16 pSS
patients with active disease investigated the use of
epratuzumab, a humanized anti-CD22 monoclonal
antibody, over 4 infusions of 360 mg/m2 once every
2 weeks, with 6 months of follow-up, showing efﬁcacy
in fatigue VAS.70
Similarly, abatacept, a selective modulator of costimu-
lation of T cells, seemed to be effective in improving MFI,
as well EULAR Sjögren’s Syndrome Disease Activity
Index (ESSDAI) and ESSPRI, in an open-label study
including 15 patients. Eight intravenous abatacept infu-
sions (10 mg/kg) were administered over 24 weeks of
treatment with a follow-up at weeks 36 and 48.71
TNFα blockers, however, did not improve fatigue.
Inﬂiximab showed no efﬁcacy, including fatigue VAS, in
a double-blind, placebo-RCT including 103 patients
receiving infusions of 5 mg/kg at weeks 0, 2, and 6 and
followed up after 22 weeks.72
Similarly, just four of the 15 pSS patients included in
a pilot study using etanercept subcutaneously twice per week
for 12 weeks, with follow up visits at 18 and 24 weeks
reported reduction in MFI.73
Animal studies support IL-1 receptors as potential tar-
gets. Dantzer et al report animal data demonstrating that
sickness behavior is signaled through IL-1 receptors in the
brain.74 In human studies, patients with pSS have higher
levels of IL-1-RA in the cerebrospinal ﬂuid with respect to
controls, and its concentration correlated with fatigue.75
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Norheim et al designed a double-blind RCT including
26 patients to test anakinra, a recombinant IL-1 receptor
antagonist. However, while half of the patients in the
active drug group reported a 50% reduction in fatigue
VAS, compared to just one patient in the placebo group,
there was no statistically signiﬁcant reduction in the pri-
mary endpoint analysis using fatigue VAS. There were no
signiﬁcant changes in FSS scores between groups.76
May non-pharmacological
interventions be potential
treatments for fatigue in SSp?
Despite their potential, the only published non-
pharmacological intervention that appears to be effective, is
aerobic exercise. One problem is that complex interrelation-
ships between physical activity, depression, sleep disturbances
and pain in the pathophysiology of fatigue in pSS may make
RCTs using fatigue as the primary outcome measure difﬁcult
to separate from confounding factors. However, in view of the
possible adverse effects and substantial costs of biological
therapies and the promising results of nonpharmacological
studies from other rheumatic diseases, such interventions
could be a great potential in the management of fatigue.
Exercise
While exercise is recommended for the treatment of fatigue
in pSS in recent guidelines48–51 and review studies,77,78 this
is based largely on a single, relatively small (training
group=9; control group=10) non-randomized control study
of aerobic exercise in pSS. This study reported improve-
ments in fatigue VAS (but not in Proﬁle of fatigue, Pro-F),
aerobic capacity, depression, and physical function. The
training group performed a Nordic walking exercise three
times a week for 12 weeks. The intensity of the prescribed
exercise increased progressively over the training from
60–70% to a maximum of 70–80% of the age-predicted
maximum heart rate (220 minus the age of the
individual).79 However, this study was not included in the
systematic review of Hackett et al on non-pharmacological
treatment in pSS, as participants were not randomized.80
Miyamoto et al in a RCT with intention-to-treat analysis
(training group=23; control group=22), demonstrated that
a 16-week supervised walking program improves aerobic
capacity, exercise tolerance, patient perception of improve-
ment and fatigue measured by Functional Assessment of
Chronic Illness Therapy-Fatigue (FACIT-F) without exacer-
bating disease activity in women with pSS. Fatigue ESSPRI
domain did not show a signiﬁcant reduction. The intensity of
the exercise was based on the heart rate at 80% of the
maximum heart rate reached in the treadmill test.
Increasing the duration of exercise was made by time from
20 to 50 mins of effective walking.81
Other interventions
Other non-pharmacological interventions are the subject of
recent studies. Tarn et al investigated the effect of
a noninvasive vagus nerve stimulation device twice daily
for a 26-day period in 15 female pSS patients ﬁnding
a signiﬁcant reduction in daytime sleepiness and Pro-F
(but not in fatigue VAS). Authors suggest that the vagus
nerve may play a role in the regulation of fatigue and
immune responses in pSS. However, a RCT including
a larger sample size is needed.82
Hackett et al argue for a personalized, holistic
approach, delivered by a multidisciplinary care team.
This empowers patients by taking their health concerns
seriously. Patients may be supported to self-managing
aspects of their condition, especially their key symptoms
of dryness, fatigue, pain, and poor sleep.83 Data from
50 pSS patients attended at the Newcastle CRESTA
Fatigue clinic, a UK National Health Service multidisci-
plinary clinic, showed an improvement in fatigue VAS
scores and were maintained at 6–12 months follow-up.
After the medical review of fatigue (including autonomic
dysfunction, untreated comorbidities, and a medication
review), therapy interventions are tailored according to
the needs of the patient and may include occupational
therapy (activity management), physiotherapy (core-
strengthening exercises) and health psychology.84
One of the key interventions targeting self-management is
patient education. This is deﬁned as “planned organised
learning experiences designed to support and enable people
to manage life with their condition and optimise their health
and well-being”.85 However, there is no study investigating
the effect of a patient education program in pSS. In general
chronic diseases, when compared to usual care,
self-management programs have a small but statistically
signiﬁcant short-term improvement in fatigue, pain,
disability, depression, health distress, self-rated health, and
health-related quality of life, but not anxiety or depression.86
In addition to self-management and patient education,
other psychosocial interventions have demonstrated
a small beneﬁt for managing fatigue in people with rheu-
matoid arthritis, such as cognitive behavioral therapy
(CBT)87,88 and mindfulness.87 But there is no study
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performed in pSS. CBT is well recognized for psycholo-
gical conditions such as depression or anxiety. However,
CBT is weakly recommended in the guidelines for the
management of ﬁbromyalgia,89 and there is inconsistent
to weak evidence to treat chronic fatigue syndrome.90
Mindfulness, a non-judgmental, present moment
awareness meditation, has been shown to improve psycho-
logical well-being via improved cognitive and emotional
reactivity.91 There is only limited evidence that this and
other multi-modal approaches are effective for improving
patient-reported outcomes and emotional disturbances
related to rheumatoid arthritis.92
Sleep management may be important. Current recom-
mendations include sleeping at a regular bedtime, avoid
oversleeping and schedule breaks at work or during day
at home for management of fatigue.93 Hackett et al report
an increased prevalence of sleep disturbances in pSS
patients compared with controls94 and suggest cognitive
behavior therapy for insomnia (CBT-I) may be an appro-
priate treatment.23 This approach has not yet been tested
in pSS, but there is evidence that it improves sleep,
fatigue, and other quality-of-life outcomes in ﬁbromyal-
gia patients.95 Usmani et al reported a higher frequency
of obstructive apneas and hypopneas detected by poly-
somnography in pSS. These were doubled in the pSS
group compared with controls. Five patients identiﬁed
as having severe sleep apnoea were treated with contin-
uous positive airway pressure (CPAP) resulting in sig-
niﬁcant improvements in both daytime sleepiness and
fatigue, but not depression or anxiety.96
Possible solutions
There is still a long way to go to ﬁnd solutions to
manage fatigue in pSS. Certainly, the fragmented
knowledge of the pathophysiological mechanisms of
pSS, and especially of fatigue, is the main obstacle to
ﬁnd them. It is likely that basic research associated with
therapeutic research may show more about the patho-
genesis of pSS/fatigue and, consequently, deﬁne the
most appropriate therapeutic approach. High-quality
RCT for potential pharmacological and non-
pharmacological interventions must be performed.
However, the recommendation for the best patient-
reported outcome measures for fatigue in pSS through
a systemic review with meta-analysis is an urgent and
essential need to standardize the evaluation methods in
the RCTs and to guarantee valid and reliable results.
New knowledge about the pathogenesis of autoim-
mune diseases may lead to a new therapeutic approach
in pSS. It is known that Janus kinase–Signal Transducers
and Activators of Transcription (JAK–STAT) pathway
play a central role in the pathogenesis of autoimmune
diseases.97 Janus Kinases inhibitors (tofacitinib) have
shown signiﬁcant improvement in fatigue in rheumatoid
arthritis,98 but have yet to be tested in pSS. Sphingosine-
1-phosphate (S1P) enhances proliferation and IFN-γ pro-
duction by CD4+T cells in pSS patients.99 Sphingosine-
1-phosphate receptor (S1PR) modulators (ﬁngolimod and
siponimod) might provide potential treatment for several
autoimmune diseases100 such as pSS.
Conclusion
Fatigue is a frequent and disabling symptom of pSS. The
unknown pathophysiology of fatigue makes it difﬁcult to
determine a speciﬁc treatment for this symptom. Synthetic
or biologic drugs have so far failed to show signiﬁcant
efﬁcacy in improving fatigue. The role of HCQ remains
unclear; RTX is questionable; LEF, zidovudine, bortezo-
mib, TGP, belimumab, epratuzumab, abatacept, etanercept,
and anakinra require further research. Other treatments
such as dehydroepiandrosterone, gamma-linolenic acid,
doxycycline, and inﬂiximab are not effective based on
available data.
Robust studies using non-pharmacological approaches
are urgently needed. Non-pharmacological approaches are
inherently attractive offering fewer adverse effects than
drug treatments, and there are some data to support their
use from other rheumatic diseases. Aerobic exercise seems
to be effective and safe suggesting an important role for
physical ﬁtness in the pathogenesis of fatigue.
Nonetheless, long-term RCTs are needed and other types
of exercise should be explored too. CPAP is considered the
most efﬁcacious method to treat sleep apnea.101 However,
the effect of CPAP or any other intervention for sleep
disorders in pSS should be investigated by RCTs, as well
as non-invasive vagus nerve stimulation, patient education
programs or psychological techniques.
Much of the data comes from small trials, or the results
of open-label studies that are not conﬁrmed in RCTs, and
there are few studies with long-term follow-up. One of the
obstacles to trials in this area is the difﬁculties in measur-
ing fatigue. Fatigue VAS scales may be of limited value.
With the exception of PROFAD/ProF and ESSPRI fatigue
domain, it is not possible to assume that the other
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instruments would have measures and practical properties
of consistent measures in the population with pSS.
In addition, further studies exploring the pathogenesis of
fatigue in pSS are crucial to guide therapeutic development.
Certainly, in clinical practice, the multi-dimensional nature of
fatigue suggests that effective management of pSS-associated
fatigue may require a patient-centric, multidisciplinary
approach.
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